NDA (New Drug Application)
ANDA (Generic Application)
It is formulated by 1 pharmaceutical company such as BAYER HLTHCARE. It is marketed under 1 brand name, including XOFIGO. Available in 1 different strength, such as 162mCi/6ML (27mCi/ML), and administered through 1 route including SOLUTION;INTRAVENOUS.
Track protection status across key markets to assess launch feasibility.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
FDA approval history for this ingredient
Key expiration dates for US patents covering this ingredient
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
No US Orange Book patents found
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
No suppliers found.
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.